Mengnan Liu

Dr. Mengnan Liu

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2024 in Life Sciences
Verified
Journal Article
Closed access
LCLi Chen
Li Chen
LMLin-Shen Mao
Lin-Shen Mao
JXJin-Yi Xue
Jin-Yi Xue
YJYu-Hong Jian
Yu-Hong Jian
ZDZi-Wen Deng
Zi-Wen Deng
MLMengnan Liu
Mengnan Liu

8 November 2024 in Phytomedicine
Verified
Journal Article
Closed access
MCMingtai Chen
Mingtai Chen
RWRaoqiong Wang
Raoqiong Wang
LLLishang Liao
Lishang Liao
YLYuanyuan Li
Yuanyuan Li
XSXingyu Sun
Xingyu Sun
MLMengnan Liu
Mengnan Liu

20 January 2025 in Apoptosis
Verified
Journal Article
Closed access
PDF file
HWHao Wu
Hao Wu
QLQi Lan
Qi Lan
YHYi-Xiang He
Yi-Xiang He
JXJin-Yi Xue
Jin-Yi Xue
HLHao Liu
Hao Liu
MLMengnan Liu
Mengnan Liu


2 December 2023 in Heliyon
Verified
Journal Article
Open access
GLGang Luo
Gang Luo
LCLi Chen
Li Chen
MCMingtai Chen
Mingtai Chen
LMLinshen Mao
Linshen Mao
QZQihu Zeng
Qihu Zeng
MLMengnan Liu
Mengnan Liu
Cardiomyocyte hypertrophy due to hemodynamic overload eventually leads to heart failure. Hirudin has been widely used in the treatment of cardiovascular diseases and NLRP3 inflammasome was proven to induce cardiomyocyte pyroptosis. However, the mechanism by which it inhibits cardiomyocyte hypertrophy remains unclear. To explore the mechanism of hirudin inhibiting cardiomyocyte hypertrophy based on NLRP3 inflammasome activation and mitophagy. 1 μM AngII was used for cardiac hypertrophy modeling in H9C2 cells, and cell viability was quantified by CCK-8 assay to screen the appropriate action concentrations of hirudin. After that, we cultured AngII induced-H9C2 cells for 24 h with 0, 0.3, 0.6, and 1.2 mM hirudin, respectively. Next, we marked H9C2 cells with phalloidine and observed them using fluorescence microscope. IL-1β, IL-18, IL-6, TNF-α, ANP, BNP, β-MHC, and mtDNA were analyzed by qRT-PCR; ROS were quantified by Flow cytometry; SOD, MDA, and GSH-Px were detected by ELISA; and proteins including NLRP3, ASC, caspase-1, pro-caspase-1, IL-1β, IL-18, PINK-1, Parkin, beclin-1, LC3-Ⅰ, LC3-Ⅱ, p62, were quantified by western blotting. It was discovered that hirudin reduced the superficial area of AngII-induced H9C2 cells and inhibited the AngII-induced up-regulation of ANP, BNP, and β-MHC. Besides, hirudin down-regulated the expressions of NLRP3 inflammasome-related cytokines, containing IL-1β, IL-18, IL-6, TNF-α. It also down-regulated the expression of mtDNA and ROS, decreased the expression levels of NLRP3 inflammasome activation related proteins, including NLRP3, ASC, caspase-1, pro-caspase-1, IL-1β, IL-18; and increased the expressions of PINK-1, Parkin, beclin-1, LC3-Ⅱ/LC3-Ⅰ, p62 in AngII-induced H9C2 cells. Hirudin promoted the process of mitophagy, inhibited the development of inflammation and oxidative stress, and inhibited the activation of the NLRP3 inflammasome and the PINK-1/Parkin pathway. Hirudin has the activity to suppress cardiac hypertrophy may benefit from the inhibition of NLRP3 inflammasome and activating of PINK-1/Parkin related-mitophagy.

12 November 2024 in International Immunopharmacology
Verified
Journal Article
Closed access
YYYou Yang
You Yang
AWAi Wu
Ai Wu
ADAn-Ni Deng
An-Ni Deng
HLHao Liu
Hao Liu
QLQi Lan
Qi Lan
MLMengnan Liu
Mengnan Liu